Sutro Biopharma raises $110M in underwritten public offering of 7.87M shares at $13.98/share

SUTRO BIOPHARMA, INC.

Offering of 7,868,383 shares at $13.98 per share; gross proceeds approximately $110.0 million.
Underwriters include Leerink Partners and TD Securities; closing expected February 11, 2026.
Proceeds to fund research, clinical development, manufacturing, and general corporate purposes.
Combined with existing cash, total capital resources estimated at $251.4 million; cash runway into Q2 2028.
Offering made under existing shelf registration statement; customary underwriting agreement terms.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.